» Articles » PMID: 19461040

Lipoprotein-associated Phospholipase A2 and C-reactive Protein for Risk-stratification of Patients with TIA

Overview
Journal Stroke
Date 2009 May 23
PMID 19461040
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a marker of unstable atherosclerotic plaque, and is predictive of both primary and secondary stroke in population-based studies.

Methods: We conducted a prospective study of patients with acute TIA who presented to the ED. Clinical risk scoring using the ABCD(2) score was determined and Lp-PLA(2) mass (LpPLA(2)-M) and activity (LpPLA(2)-A) and high-sensitivity C-reactive protein (CRP) were measured. The primary outcome measure was a composite end point consisting of stroke or death within 90 days or identification of a high-risk stroke mechanism requiring specific early intervention (defined as >or=50% stenosis in a vessel referable to symptoms or a cardioembolic source warranting anticoagulation).

Results: The composite outcome end point occurred in 41/167 (25%) patients. LpPLA(2)-M levels were higher in end point-positive compared to -negative patients (mean, 192+/-48 ng/mL versus 175+/-44 ng/mL, P=0.04). LpPLA(2)-A levels showed similar results (geometric mean, 132 nmol/min/mL, 95% CI 119 to 146 versus 114 nmol/min/mL, 95% CI 108 to 121, P=0.01). There was no relationship between CRP and outcome (P=0.82). Subgroup analysis showed that both LpPLA(2)-M (P=0.04) and LpPLA(2)-A (P=0.06) but not CRP (P=0.36) were elevated in patients with >50% stenosis. In multivariate analysis using cut-off points defined by the top quartile of each marker, predictors of outcome included LpPLA(2)-A (OR 3.75, 95% CI 1.58 to 8.86, P=0.003) and ABCD(2) score (OR 1.30 per point, 95% CI 0.97 to 1.75, P=0.08).

Conclusions: Many patients with TIA have a high-risk mechanism (large vessel stenosis or cardioembolism) or will experience stroke/death within 90 days. In contrast to CRP, both Lp-PLA(2) mass and activity were associated with this composite end point, and LpPLA(2)-A appears to provide additional prognostic information beyond the ABCD(2) clinical risk score alone.

Citing Articles

Associations between admission levels of multiple biomarkers and subsequent worse outcomes in acute ischemic stroke patients.

Jia W, Jiang Y, Jiang Y, Meng X, Li H, Zhao X J Cereb Blood Flow Metab. 2023; 44(5):742-756.

PMID: 37975323 PMC: 11197142. DOI: 10.1177/0271678X231214831.


Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study.

Li J, Lin J, Pan Y, Wang M, Meng X, Li H J Neuroinflammation. 2022; 19(1):131.

PMID: 35761288 PMC: 9235241. DOI: 10.1186/s12974-022-02467-1.


Lp-PLA2 as a biomarker and its possible associations with SARS-CoV-2 infection.

Dua P, Mishra A, Reeta K Biomark Med. 2022; 16(10):821-832.

PMID: 35694871 PMC: 9196258. DOI: 10.2217/bmm-2021-1129.


Biomarkers for Transient Ischemic Attack: A Brief Perspective of Current Reports and Future Horizons.

Nouri-Vaskeh M, Khalili N, Sadighi A, Yazdani Y, Zand R J Clin Med. 2022; 11(4).

PMID: 35207321 PMC: 8877275. DOI: 10.3390/jcm11041046.


Exploring potential serum levels of Homocysteine, interleukin-1 beta, and apolipoprotein B 48 as new biomarkers for patients with ischemic stroke.

Shademan B, Nourazarian A, Laghousi D, Karamad V, Nikanfar M J Clin Lab Anal. 2021; :e23996.

PMID: 34492129 PMC: 8551691. DOI: 10.1002/jcla.23996.